Adocia (fra:A89) Share Price

Company Profile

Business description
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
Contact
115 Avenue Lacassagne
Lyon69003
FRA
T: +33 472610610
https://www.adocia.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
76

Recommended

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.

Malik Ahmed Khan, CFA | 08 January 2026

Wagering continues to be challenged in Australia.

Angus Hewitt, CFA | 08 January 2026

Rising inflation is the fly in the ointment.

Simonelle Mody | 08 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,045.90	27.80	-0.31%
CAC 40	8,312.28	78.36	0.95%
DAX 40	25,202.23	74.77	0.30%
Dow JONES (US)	49,266.11	270.03	0.55%
FTSE 100	10,089.52	44.83	0.45%
HKSE	26,231.79	82.48	0.32%
NASDAQ	23,480.02	104.26	-0.44%
Nikkei 225	51,939.89	822.63	1.61%
NZX 50 Index	13,696.25	20.61	-0.15%
S&P 500	6,921.46	0.53	0.01%
S&P/ASX 200	8,717.80	29.10	-0.33%
SSE Composite Index	4,120.43	37.45	0.92%